<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pyrimethamine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pyrimethamine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pyrimethamine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9841" href="/d/html/9841.html" rel="external">see "Pyrimethamine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11417" href="/d/html/11417.html" rel="external">see "Pyrimethamine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F216093"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Daraprim</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1049610"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antimalarial Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462571"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oral leucovorin should be administered throughout the entire course to prevent hematologic toxicity (AAP [<i>Red Book</i> 2018]; HHS [OI pediatric 2019]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9bb7a71f-edc7-4054-bf29-7790f7c6acec">Congenital toxoplasmosis; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital toxoplasmosis (independent of HIV status); treatment:</b> In combination with sulfadiazine and leucovorin: Oral: Initial: 2 mg/kg/day once daily or in 2 divided doses for 2 days, then 1 mg/kg/day once daily for 2 to 6 months, then 1 mg/kg/dose 3 times weekly (eg, Monday, Wednesday, Friday); total treatment duration: 12 months (AAP [<i>Red Book</i> 2018]; HHS [OI pediatric 2019]).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F216114"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oral leucovorin should be administered throughout the entire course to prevent hematologic toxicity (AAP [<i>Red Book</i> 2018]; HHS [OI pediatric 2019]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf0fa14e-2009-4591-a442-b618e552698c">Cystoisosporiasis, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystoisosporiasis<i> (formerly isosporiasis)</i>, HIV-exposed/-infected:</b> Alternative therapy to sulfamethoxazole/trimethoprim.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<span style="text-decoration: underline">Treatment</span></i>
<span style="text-decoration: underline">: </span></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 1 mg/kg/day once daily in combination with leucovorin for 14 days; maximum daily dose: 25 mg/<b>day </b>(HHS [OI pediatric 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 50 to 75 mg once daily in combination with leucovorin (HHS [OI adult 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">
<i>Chronic maintenance (secondary prophylaxis): </i></span></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 1 mg/kg/day once daily in combination with leucovorin; maximum daily dose: 25 mg/<b>day</b> (HHS [OI pediatric 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 25 mg once daily in combination with leucovorin (HHS [OI adult 2019]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38c6f9d2-31e2-467e-8bea-d2654e81016f">
<i>Pneumocystis jirovecii</i> pneumonia, HIV-exposed/-infected; primary prophylaxis or chronic maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii</i></b>
<b> pneumonia (PCP), HIV-exposed/-infected; primary prophylaxis or chronic maintenance (secondary prophylaxis):</b> Alternative therapy (HHS [OI adult 2019]):</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">In combination with dapsone and leucovorin: 50 to 75 mg once <b>weekly</b> (dose depends on dapsone dose).</p>
<p style="text-indent:-2em;margin-left:6em;">In combination with atovaquone and leucovorin: 25 mg once <b>daily</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="881af723-012a-4791-8964-f10c41eda7d4">Toxoplasmosis, acquired infection; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis, acquired infection (including encephalitis); treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HIV-exposed/-infected: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 2 mg/kg/day (maximum dose: 50 mg/dose) once daily for 3 days followed by 1 mg/kg/day once daily (maximum dose: 25 mg/dose) in combination with leucovorin and either sulfadiazine or clindamycin; treat for at least 6 weeks; consider longer duration if clinical or radiologic disease is extensive or incomplete response; follow with chronic suppressive therapy in patients experiencing encephalitis (HHS [OI pediatric 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: Encephalitis: 200 mg once as a single dose, followed by weight-based daily dosing; treat for at least 6 weeks (HHS [OI adult 2019]):</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;60 kg: 50 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥60 kg: 75 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-HIV-exposed/-infected</i> (<i>Red Book</i> [AAP 2018]):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use in combination with leucovorin and either sulfadiazine or clindamycin.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;60 kg: Oral: Initial: 2 mg/kg/day in divided doses twice daily for 2 days (maximum dose: Chorioretinitis: 25 mg/dose; severe or CNS disease: 50 mg/dose); followed by 1 mg/kg/day once daily (maximum dose: Chorioretinitis: 25 mg/dose; severe or CNS disease: 50 mg/dose). Continue therapy for 1 to 2 weeks after symptom resolution, for a total therapy of 4 to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">≥60 kg: Oral: Initial: 2 mg/kg/day in divided doses twice daily for 2 days (maximum dose: Chorioretinitis: 25 mg/dose; severe or CNS disease: 50 mg/dose); followed by 1 mg/kg/day once daily (maximum dose: Chorioretinitis: 25 mg/dose; severe or CNS disease: 75 mg/dose). Continue therapy for 1 to 2 weeks after symptom resolution, for a total therapy of 4 to 6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c08c095-786c-48c9-9e11-8335ad7f03bf">Toxoplasmosis, congenital infection; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis, congenital infection (independent of HIV status); treatment:</b> In combination with sulfadiazine and leucovorin:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Oral: Initial: 2 mg/kg/day once daily or in 2 divided doses for 2 days, then 1 mg/kg/day once daily for 2 to 6 months, then 1 mg/kg/dose 3 times <b>weekly</b> (eg, Monday, Wednesday, Friday); maximum dose: 25 mg/dose; total treatment duration: 12 months (AAP [<i>Red Book</i> 2018]; HHS [OI pediatric 2019]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ae54f7b-7163-42ba-958f-ea5d4203730a">Toxoplasmosis, prophylaxis, in hematopoietic cell transplantation recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis, prophylaxis, in hematopoietic cell transplantation recipients</b> (Tomblyn 2009):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: 1 mg/kg/day once daily with clindamycin and leucovorin; maximum dose: 75 mg/dose. Start after engraftment and administer as long as the patient remains on immunosuppressive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 25 to 75 mg once daily with clindamycin and leucovorin. Start after engraftment and administer as long as the patient remains on immunosuppressive therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cce1d583-db0b-4a4e-927d-3d617318350b">Toxoplasmosis, prophylaxis, in HIV-exposed/-infected patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis, prophylaxis, in HIV-exposed/-infected patients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis: </i>Alternative therapy to sulfamethoxazole/trimethoprim:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children (HHS [OI pediatric 2019]): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">In combination with dapsone and oral leucovorin: 1 mg/kg/day once daily; maximum dose: 25 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">In combination with atovaquone and oral leucovorin: Infants and Children 4 to 24 months: 1 mg/kg/day or 15 mg/m<sup>2</sup>/day once daily; maximum dose: 25 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents (HHS [OI adult 2019]): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">In combination with dapsone and oral leucovorin: 50 mg or 75 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">In combination with atovaquone and oral leucovorin: 25 mg once <b>daily</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis/suppressive therapy</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 1 mg/kg/day or 15 mg/m<sup>2</sup>/day once daily (maximum dose: 25 mg/dose) with leucovorin and sulfadiazine, clindamycin, or atovaquone (HHS [OI pediatric 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents (HHS [OI adult 2019]): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">In combination with sulfadiazine or clindamycin: 25 to 50 mg once daily plus leucovorin.</p>
<p style="text-indent:-2em;margin-left:8em;">In combination with atovaquone: 25 mg once daily plus leucovorin.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159537"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51159538"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F216098"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9841" href="/d/html/9841.html" rel="external">see "Pyrimethamine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3c161a5-e0dd-4327-8695-ce4243967f59">Cystoisosporiasis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystoisosporiasis (formerly Isosporiasis) in patients with HIV (alternative agent)</b>
<b>(off-label use):</b></p>
<p style="text-indent:0em;margin-left:2em;">
<b>Note: </b>For patients unable to use sulfa agents (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute infection, treatment:</i>
<b>Oral:</b> 50 to 75 mg once daily in combination with leucovorin calcium (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic maintenance therapy (secondary prophylaxis):</i>
<b>Oral: </b>25 mg once daily in combination with leucovorin calcium (HHS [OI adult 2022]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b6d76e0-daa4-4f7d-820b-c477162bb88f">
<i>Pneumocystis</i> pneumonia in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis </i>pneumonia in patients with HIV (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis:</i>
<b>Oral: </b>50 or 75 mg once weekly in combination with dapsone and leucovorin calcium; <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic maintenance therapy (secondary prophylaxis): </i>
<b>Oral:</b> 50 to 75 mg once weekly in combination with dapsone and leucovorin calcium; <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy: </i>Continue until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months in response to antiretroviral therapy (ART); some experts discontinue prophylaxis in patients with CD4 counts between 100 and 200 cells/mm<sup>3 </sup>who are receiving ART and have had an undetectable viral load for ≥3 to 6 months. If <i>Pneumocystis</i> pneumonia occurs at a CD4 count &gt;200 cells/mm<sup>3</sup> in a patient who is not on ART, consider discontinuing secondary prophylaxis once viral load is undetectable for ≥3 to 6 months; if <i>Pneumocystis</i> pneumonia occurs at a CD4 count &gt;200 cells/mm<sup>3</sup> while a patient is on ART, secondary prophylaxis is lifelong (HHS [OI adult 2022]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e41af1d-f57a-4044-bfa3-84beb015adc1">Toxoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Patients with HIV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary prophylaxis (alternative agent) (off-label use):</i>
<b>Oral: </b>50 or 75 mg once weekly in combination with dapsone and leucovorin calcium; <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium. Continue until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months in response to ART; some experts discontinue prophylaxis in patients with CD4 counts between 100 and 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Encephalitis, treatment (off-label):</i>
<b>Oral: </b>200 mg as a single dose, followed by 50 mg once daily (patient weight &lt;60 kg) or 75 mg once daily (patient weight ≥60 kg), in combination with sulfadiazine and leucovorin calcium for at least 6 weeks; <b>or</b> 200 mg as a single dose, followed by 50 mg once daily (patient weight &lt;60 kg) or 75 mg once daily (patient weight ≥60 kg) in combination with leucovorin calcium plus clindamycin or atovaquone (alternative regimens). <b>Note:</b> If pyrimethamine is unavailable or there is a procurement delay, trimethoprim-sulfamethoxazole should be used in place of pyrimethamine-containing regimens until pyrimethamine is available (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chronic maintenance therapy (secondary prophylaxis) (off-label use): </i>
<b>Oral:</b> 25 to 50 mg once daily in combination with sulfadiazine and leucovorin calcium; <b>or</b> 25 to 50 mg once daily in combination with clindamycin and leucovorin calcium (alternative regimen); <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium (alternative regimen). May discontinue in patients who successfully complete initial treatment regimen, remain asymptomatic of signs/symptoms of <i>Toxoplasma gondii</i> encephalitis, and have a CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months in response to ART (HHS [OI adult 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Patients without HIV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment: </i>
<b>Oral:</b> 50 to 75 mg once daily in combination with a sulfonamide and leucovorin calcium for 1 to 3 weeks depending on patient's tolerance and response, then may reduce dose by 50% and continue for 4 to 5 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991649"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution. </p></div>
<div class="block doha drugH1Div" id="F50988951"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution. </p></div>
<div class="block adr drugH1Div" id="F216059"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia (large doses)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Erythema multiforme, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Anorexia, glossitis (atrophic), vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Leukopenia, megaloblastic anemia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Eosinophilic pneumonitis</p></div>
<div class="block coi drugH1Div" id="F216074"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pyrimethamine or any component of the formulation; megaloblastic anemia secondary to folate deficiency</p></div>
<div class="block war drugH1Div" id="F216056"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic: Megaloblastic anemia, leukopenia, thrombocytopenia, neutropenia, and pancytopenia have been reported; most commonly with high doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Folate deficiency: Use caution in patients with possible folate deficiency (eg, malabsorption syndrome, alcoholism).</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use with caution in patients with possible G6PD deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Leucovorin: Administer leucovorin to prevent hematologic complications due to pyrimethamine-induced folic acid deficiency state; continue leucovorin during therapy and for 1 week after therapy is discontinued (to account for long half-life of pyrimethamine) (HHS [OI pediatric 2019])</p></div>
<div class="block foc drugH1Div" id="F216067"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Daraprim: 25 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Daraprim: 25 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block geq drugH1Div" id="F216052"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F216077"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Daraprim Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $900.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pyrimethamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $796.88 - $855.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F216072"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>2 mg/mL oral suspension</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 2 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Simple Syrup, NF and methylcellulose 1%. Crush forty 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to <b>almost</b> 500 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 500 mL. Label "shake well" and "refrigerate". Stable for 91 days.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52613752"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals to minimize loss of appetite and/or vomiting.</p></div>
<div class="block adm drugH1Div" id="F216070"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with meals to minimize GI distress.</p></div>
<div class="block sts drugH1Div" id="F216089"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 25°C (59°F to 77°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568601"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Used in combination with a sulfonamide for treatment of toxoplasmosis (FDA approved in pediatric patients [age not specified] and adults); has also been used in combination with dapsone as primary or secondary prophylaxis for <i>Pneumocystis jirovecii</i> in HIV-infected patients.</p></div>
<div class="block mst drugH1Div" id="F216134"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Daraprim may be confused with Dantrium, Daranide</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F216123"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F216061"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Artemether and Lumefantrine.  Management: Artemether/lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. If combined, monitor patients for increased toxicities of both agents, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Antimalarial Agents may increase the serum concentration of ChlorproMAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Consider avoidance of this combination when possible. If combined, closely monitor for signs/symptoms of hemolytic reactions. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: MATE1/2-K Inhibitors may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: May diminish the therapeutic effect of Pyrimethamine. Management: Folic acid doses greater than 2.5 mg per day should be avoided due to the potential for sulfadoxine/pyrimethamine treatment failure. Consider limiting folic acid use to no more than 0.4 mg per day for women of child-bearing age.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LORazepam: May enhance the hepatotoxic effect of Pyrimethamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: MATE1/2-K Inhibitors may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Pyrimethamine may enhance the adverse/toxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylfolate: May diminish the therapeutic effect of Pyrimethamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PEMEtrexed: Pyrimethamine may enhance the adverse/toxic effect of PEMEtrexed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Pyrimethamine may enhance the adverse/toxic effect of PRALAtrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: Pyrimethamine may enhance the adverse/toxic effect of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltitrexed: Pyrimethamine may enhance the adverse/toxic effect of Raltitrexed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: Pyrimethamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: Pyrimethamine may enhance the adverse/toxic effect of Trimethoprim. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F9603935"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F53611293"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy should be avoided during therapy.</p></div>
<div class="block pri drugH1Div" id="F216078"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pyrimethamine should be used with caution in patients with possible folate deficiency, including pregnant patients. If administered during pregnancy (ie, for toxoplasmosis), supplementation of folate is strongly recommended.</p>
<p style="text-indent:0em;margin-top:2em;">Pyrimethamine is recommended for treatment of <i>T. gondii</i> in pregnant patients with HIV, including those with a strong suspicion of fetal infection. Pyrimethamine should not be used in the first trimester (HHS [OI adult 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53568589"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, including platelet counts twice weekly with high-dose therapy (eg, when used for toxoplasmosis treatment; frequency not defined for lower doses); liver and renal function </p></div>
<div class="block pha drugH1Div" id="F216055"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits parasitic dihydrofolate reductase, resulting in inhibition of vital tetrahydrofolic acid synthesis</p></div>
<div class="block phk drugH1Div" id="F216073"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Adults: 2.9 L/kg; distributed to the kidneys, lung, liver, and spleen</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 87% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 80 to 95 hours (White 1985)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 to 6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (16% to 32%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F216080"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Daraprin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Malomin | Tindurin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim | Pirimetamina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Toxopirin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Malocide | Pyrimethamine Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tindurin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Daramin | Daraprim</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Xoprim</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Daraprim | Tindurin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim | Tindurin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Daraprim | Pirimetamina</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Daraprim | Malocide | Pyrimen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Daraprim | Pirimetamina</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A bin | Daraprim</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Malocide</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Daraprim</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Akinyanju.1">
<a name="Akinyanju.1"></a>Akinyanju O, Goddell JC, Ahmed I. Pyrimethamine Poisoning. <i>Br Med J</i>. 1973;4(885):147-148.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11941551">
<a name="11941551"></a>Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study, <i>Clin Infect Dis</i>. 2002;34(9):1243-1250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/11941551/pubmed" id="11941551" target="_blank">11941551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chute.1">
<a name="Chute.1"></a>Chute JP, Decker CF, Cotelingam J. Severe Megaloblastic Anemia Complicating Pyrimethamine Therapy. <i>Ann Intern Med</i>. 1995;122(11):884-885.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Daraprim.1">
<a name="Daraprim.1"></a>Daraprim (pyrimethamine) [prescribing information]. New York, NY: Vyera Pharmaceuticals; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8544792">
<a name="8544792"></a>Drugs for Parasitic Infections. <i>Med Lett Drugs Ther</i>, 2002. http://www.medicalletter.com/freedocs/parasitic.pdf.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/8544792/pubmed" id="8544792" target="_blank">8544792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8838183">
<a name="8838183"></a>Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-Clindamycin vs Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients With AIDS. <i>Clin Infect Dis</i>. 1996;22(2):268-275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/8838183/pubmed" id="8838183" target="_blank">8838183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2138674">
<a name="2138674"></a>Phillips-Howard PA West LJ. Serious Adverse Drug Reactions to Pyrimethamine-Sulfadoxine, Pyrimethamine-Dapsone, and to Amodiaquine in Britain. <i>J R Soc Med</i>. 1990;83(2):82-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/2138674/pubmed" id="2138674" target="_blank">2138674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1359410">
<a name="1359410"></a>Porter SB, Sande MA. Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome. <i>N Engl J Med</i>. 1992;327(23):1643-1648.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/1359410/pubmed" id="1359410" target="_blank">1359410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624473">
<a name="9624473"></a>Torre D, Casari S, Speranza F, et al. Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group. <i>Antimicrob Agents Chemother</i>. 1998;42(6):1346-1349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/9624473/pubmed" id="9624473" target="_blank">9624473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Accessed November 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>.Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2121456">
<a name="2121456"></a>Van Voorhis WC. Therapy and Prophylaxis of Systemic Protozoan Infections. <i>Drugs</i>. 1990;40(2):176-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/2121456/pubmed" id="2121456" target="_blank">2121456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3893840">
<a name="3893840"></a>White NJ. Clinical Pharmacokinetics of Antimalarial Drugs. <i>Clin Pharmacokinet</i>. 1985;10(3):187-215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/3893840/pubmed" id="3893840" target="_blank">3893840</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12754 Version 225.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
